

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 March 2002 (21.03.2002)

PCT

(10) International Publication Number  
**WO 02/22883 A1**

- (51) International Patent Classification: C12Q 1/68: (74) Agent: WHITE, John, P.: Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY 10036 (US).  
C07H 21/04
- (21) International Application Number: PCT/US01/28967 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date:  
11 September 2001 (11.09.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
09/658,077 11 September 2000 (11.09.2000) US  
60/309,156 31 July 2001 (31.07.2001) US
- (71) Applicant (for all designated States except US): THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [US/US]; West 116th Street & Broadway, New York, NY 10027 (US).
- (72) Inventors: and
- (75) Inventors/Applicants (for US only): JI, Jingyue [US/US]; 267 Marietta Street, Englewood Cliffs, NJ 07632 (US). LI, Zengmin [CN/US]; Apartment 41, 647 West 172 Street, New York, NY 10032 (US). TONG, Anthony [GB/US]; 500 Riverside Drive #652, New York, NY 10027 (US). RUSSO, James, J. [US/US]; Apartment 25E, 60 Haven Avenue, New York, NY 10032 (US).
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— with international search report  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/22883 A1

(54) Title: COMBINATORIAL FLUORESCENCE ENERGY TRANSFER TAGS AND USES THEREOF

(57) Abstract: This invention provides a combinatorial fluorescence energy transfer tag which comprises a plurality of fluorescent molecules, comprising one or more energy transfer donor and one or more energy transfer acceptor, linked through a molecular scaffold wherein the fluorescent molecules are separated along the scaffold to produce a unique fluorescence emission signature. The invention further provides for the use of said tags in multi-component analyses, including multiplex biological analyses.

COMBINATORIAL FLUORESCENCE ENERGY TRANSFER TAGS AND  
USES THEREOF

5

This application claims priority of Provisional Application no. 60/309,156, filed July 31, 2001 and is a continuation in part of U.S. Serial No. 09/658,077, filed September 11, 2000, the contents of both of which are hereby incorporated by reference into the subject application.

10

Throughout this application, various publications are referenced in parentheses by author and year. Full citations for these references may be found at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.

15

20

Background Of The Invention

25

30

The need to study many biological targets simultaneously drives the development of multiplex fluorescent tags. However, due to the limits of the spectral region, and therefore the availability of appropriate detectors, the number of available fluorescent dyes that have distinguishable emission spectra is limited to about ten. To overcome this limitation, a combinatorial fluorescent labeling approach for multi-color fluorescence in situ hybridization (M-FISH) has been developed and is now

widely used in the field of cytogenetics (Speicher et al., 1996; Schrock et al., 1996). This approach mixes from two to seven individual fluorescent dyes that have unique emissions, and uses the fluorescence emission pattern to identify the different targets. The unique fluorescence emission pattern is achieved by mathematically combining the different dyes. This development has made possible advances in chromosome analyses. However, the procedure requires physically mixing the individual dyes in a quantitative manner to develop "unique" probe labels. This requirement, coupled with the potential interactions of the dyes, complicates the fluorescence emission patterns. Therefore, the major application of the technique is limited to methods that involve hybridization. Multiple lasers and detectors are also required for the imaging. A reagent kit that can be used to covalently label a wide range of biomolecules is difficult to construct with this approach. Thus, there is an urgent need for a large set of fluorescent tags that can be used for multiple component analyses in biomedical and other fields. Previously, the principle of fluorescent energy transfer (ET) was used to enhance fluorescence emission for the successful development of four ET tags for deoxyribonucleic acid (DNA) sequencing which are widely used in the Human Genome Project (Ju et al. 1995, 1996). Tags containing fluorophores in energy transfer relationships have been disclosed in U.S. Patent 6,028,190.

Summary Of The Invention

5 This invention provides a composition of matter comprising multiple fluorophores, each of which is bound to a molecular scaffold at a separate predetermined position on the scaffold, such separate predetermined positions being selected so as to permit fluorescence energy transfer between one such  
10 fluorophore and another such fluorophore, wherein the one such fluorophore and the another such fluorophore are characterized by the maximum emission wavelength of one being greater than the minimum excitation wavelength of the other.

15 This invention further provides the instant composition of matter comprising two fluorophores, each of which is bound to a molecular scaffold, at a separate predetermined position on the scaffold, such  
20 separate positions being selected so as to permit fluorescence energy transfer between such fluorophores, and such fluorophores being characterized by the maximum emission wavelength of one of the fluorophores being greater than the  
25 minimum excitation wavelength of the other fluorophore.

This invention further provides the instant composition of matter comprising three fluorophores  
30 each of which is bound to a molecular scaffold at a separate predetermined position on the scaffold, such separate predetermined positions being selected so as

to permit fluorescence energy transfer among such fluorophores and such fluorophores being characterized by the maximum emission wavelength of one such fluorophore being greater than the minimum  
5 excitation wavelength of the second such fluorophore and the maximum emission wavelength of such second fluorophore being greater than the minimum excitation wavelength of the third such fluorophore.

10 This invention further provides the instant composition of matter, wherein each fluorophore is covalently bound to the molecular scaffold.

This invention further provides the instant  
15 composition of matter, wherein the efficiency of the fluorescence energy transfer is less than 20%.

This invention further provides the instant  
20 composition of matter, wherein the molecular scaffold is rigid.

This invention further provides the instant  
composition of matter, wherein the molecular scaffold  
is polymeric.

25 This invention further provides the instant composition of matter, wherein the molecular scaffold comprises a nucleic acid.

30 This invention further provides the instant composition of matter, wherein the molecular scaffold

comprises a peptide.

5 This invention further provides the instant composition of matter, wherein the molecular scaffold comprises a polyphosphate.

This invention further provides the instant composition of matter, wherein at least one fluorophore is a fluorescent dye.

10

This invention further provides the instant composition of matter, wherein the fluorescent dye is 6-carboxyfluorescein.

15

This invention further provides the instant composition of matter, wherein the fluorescent dye is N,N,N',N'-tetramethyl-6-carboxyrhodamine.

20


This invention further provides the instant composition of matter, wherein the fluorescent dye is cyanine-5 monofunctional dye.

25

This invention further provides the instant composition of matter, wherein at least one fluorophore is a luminescent molecule.

This invention further provides the instant composition of matter, wherein at least one fluorophore is a quantum dot.

This invention also provides a composition of matter having the structure:



10        wherein S represents a 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, each T represents a thymidine derivative, FAM represents 6-carboxyfluorescein derivative, TAM represents N,N,N',N'-tetramethyl-  
15        6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q are different.

20

This invention further provides the instant composition of matter, wherein m is 4.


25

This invention further provides the instant composition of matter, wherein m is 6.

This invention further provides the instant composition of matter, wherein m is 9.

This invention further provides the instant composition of matter, wherein m is 13.

5 This invention also provides a composition of matter having the structure:



15 wherein S represents a 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, T represents a thymidine derivative, FAM represents a 6-carboxyfluorescein derivative, Cy5 represents a cyanine-5 monofunctional dye derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents  
20 either a hydroxy or phosphate terminus, with the proviso that R and Q are different.

25 This invention further provides the instant composition of matter, wherein m is 4.

This invention further provides the instant composition of matter, wherein m is 5.




This invention further provides the instant composition of matter, wherein m is 7.

5 This invention further provides the instant composition of matter, wherein m is 10.

This invention further provides the instant composition of matter, wherein m is 13.

10

This invention also provides a composition of matter comprising the structure shown below:



20

25

wherein S represents a 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, n is an integer greater than 1 and less than 100, T represents a thymidine derivative, FAM represents a 6-carboxyfluorescein derivative, Cy5 represents a cyanine-5 monofunctional dye derivative, TAM represents a N,N,N',N'-tetramethyl-6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or

phosphate terminus, with the proviso that R and Q are different.

5 This invention further provides the instant composition of matter, wherein m is 3, and n is 7.

This invention further provides the instant composition of matter, wherein m is 4, and n is 6.


10 This invention further provides the instant composition of matter, wherein m is 5, and n is 5

This invention further provides the instant composition of matter, wherein m is 6, and n is 6.

15

This invention further provides the instant composition of matter, wherein m is 7, and n is 7.

20 This invention also provides a composition of matter comprising the structure shown below:



25

wherein S represents a 1',2'-dideoxyribose phosphate moiety, m represents an integer greater than 1 and less than 100, T represents a thymidine derivative, and TAM represents a  
5 N,N,N',N'-tetramethyl-6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q  
10 are different.

This invention further provides the instant composition of matter, wherein m is 4.

15 This invention also provides a nucleic acid labeled with any of the instant compositions.

This invention provides any of the instant compositions, wherein the nucleic acid is DNA.

20

This invention provides any of the instant compositions, wherein the nucleic acid is RNA.

25 This invention provides any of the instant compositions, wherein the nucleic acid is DNA/RNA.

This invention also provides a method of determining whether a preselected nucleotide residue is present at a predetermined position within a nucleic acid

comprising the steps of:

- 5 (a) contacting the nucleic acid, under hybridizing and DNA ligation-permitting conditions, with (i) a DNA ligase, (ii) a first oligonucleotide having affixed thereto a composition of matter of claim 1 wherein the first oligonucleotide hybridizes with nucleotides immediately adjacent one side of the predetermined position and (iii) a second oligonucleotide which hybridizes with the nucleotides immediately adjacent the other side of the predetermined position, wherein the hydroxy-terminal residue of the oligonucleotide which hybridizes to the nucleotide located 3' of the predetermined position is a nucleotide which is complementary to the preselected nucleotide residue; and
- 10
- 15
- 20 (b) detecting the presence of a ligation product comprising both the first and the second oligonucleotides, the presence of such a ligation product indicating the presence of the preselected nucleotide residue at the predetermined position.
- 25

This invention further provides a method of determining whether at various predetermined positions within a nucleic acid, a preselected nucleotide residue is present at such position, wherein the preselected nucleotide residue may vary

30

at different predetermined positions which comprises determining whether each preselected nucleotide is present each predetermined position according to the instant method.

5

This invention provides the instant method, wherein the presence of a plurality of given nucleotide residues is determined simultaneously.

10

This invention further provides the instant method, wherein the DNA ligase is Taq DNA ligase.

15

This invention further provides the instant method, wherein the second oligonucleotide has an isolation-permitting moiety affixed thereto, and wherein the method further comprises the steps of isolating the moiety-containing molecules resulting from step (a) and determining the presence therein of ligated first and second oligonucleotides.

20

25

This invention further provides the instant method, wherein the composition of matter affixed to the first oligonucleotide has a predetermined emission spectrum, and wherein the observation of this emission spectrum is employed to determine the presence of ligated first and second oligonucleotides in step (b).

30

This invention also provides a method of determining whether a preselected nucleotide residue is present

at a predetermined position within a nucleic acid comprising the steps of:

(a) contacting the nucleic acid, under hybridizing and DNA polymerization-permitting conditions, with (i) a DNA polymerase, (ii) an oligonucleotide (1) having affixed thereto a composition of matter of claim 1, and (2) having a hydroxyl 3' terminus thereof, wherein the oligonucleotide hybridizes with the 3' region of the nucleic acid molecule flanking the predetermined position, and (iii) a dideoxynucleotide labeled with an isolation-permitting moiety, wherein the labeled dideoxynucleotide is complementary to the given nucleotide residue, with the proviso that upon hybridization of the oligonucleotide with the nucleic acid in the presence of DNA polymerase and the preselected nucleotide residue, the oligonucleotide and dideoxynucleotide are juxtaposed so as to permit their covalent linkage by the DNA polymerase;

(b) detecting the presence of a polymerization product comprising both the oligonucleotide and the dideoxynucleotide, the presence of such a polymerization product indicating the presence of the preselected nucleotide residue at the predetermined position.

This invention further provides a method of determining whether at various predetermined positions within a nucleic acid, a preselected

nucleotide residue is present at such position, wherein the preselected nucleotide residue may vary at different predetermined positions which comprises determining whether each preselected nucleotide is present each predetermined position according to the instant method.

This invention further provides the instant method, wherein the DNA polymerase is thermo sequenase.

10

This invention further provides the instant method, wherein the dideoxynucleotide is selected from the group consisting of dideoxyadenosine triphosphate, dideoxycytidine triphosphate, dideoxyguanosine triphosphate, dideoxythymidine triphosphate, and dideoxyuridine triphosphate.

15

This invention further provides the instant method, wherein the composition of matter affixed to the oligonucleotide has a predetermined emission spectrum, and wherein the observation of this emission spectrum is employed to determine the presence of polymerization product in step (b).

20

This invention further provides the instant methods, wherein observing the predetermined emission spectrum is performed using radiation having a wavelength of between 200 and 1000nm.

25

This invention further provides the instant methods,

30

wherein the radiation has a wavelength of 488 nm.

This invention further provides the instant methods,  
wherein observing the predetermined emission spectrum  
5 is performed using radiation having a bandwidth of  
between 1 and 50nm.

This invention further provides the instant methods,  
wherein the radiation bandwidth is 1nm.

10

This invention further provides the instant methods,  
wherein the isolation-permitting moiety comprises  
biotin, streptavidin, phenylboronic acid,  
salicylhydroxamic acid, an antibody or an antigen.

15

This invention further provides the instant methods,  
wherein the isolation-permitting moiety is attached  
to the oligonucleotide via a linker molecule.

20

This invention further provides the instant methods,  
wherein the isolation-permitting moiety is attached  
to the dideoxynucleotide via a linker molecule.

25


This invention further provides the instant methods,  
wherein the linker molecule is chemically cleavable.

This invention further provides the instant methods,  
wherein the linker molecule is photocleavable.



This invention further provides the instant methods,  
wherein the linker molecule has the structure:

5



Brief Description Of The Figures

Figure 1A-B: (A) Schematic of a multi-chromophore assembly connected to a linker. In general, 1 to n chromophores can be attached to the assembly with the chromophores separated by spacers as shown. Chromophores can be, but not limited to, fluorescent dyes, quantum dots or luminescent molecules such as terbium chelate. A variety of spacers such as nucleotides, peptides, a polymer linker formed by 1', 2'-dideoxyribose phosphates or other chemical moieties can be used. The assembly label shown here is connected to a linker which can be designed as nucleic acids, proteins or cells, etc for multiplex biological assays. (B) The synthesis of F-4-T-6-C. The numbers in F-4-T-6-C refer to the number of spacing nucleotides in the scaffold between dyes F and T, and T and C. F = Fam; T = Tam; C = Cyanine 5 monofunctional dye.

20

Figure 2A-D: Spectroscopic data for tags F-4-T-6-C and F-7-T-3-C.

- (A) Two tags with different fluorescent signatures have been constructed by varying the spacing between the three dyes F, T, and C.
- (B) Ultraviolet/visible (UV/vis) absorption spectrum of dye F-4-T-6-C.
- (C) Fluorescence emission spectra of dye F-4-T-6-C.
- (D) Fluorescence emission spectra of dye F-7-T-3-C.
- F = Fam; T = Tam; C = Cy5.

30

Figure 3A-B: Schematic labeling approach to

construct CFET-primers and CFET-dUTPs. The spacer between dyes is 1',2'-dideoxyribose phosphate (S) in (A) and proline (P) in (B). "m" and "n" refer to the number of molecules in the spacer. dUTP = deoxyuridine triphosphate.

Figure 4: The synthesis of CFET-dUTP. The CFET tag comprises three different fluorescent dyes: Fam, Tam and Cy5.

Figure 5: Structures of Aminoallyl (AA)-dUTP, Fam-proline, and N-Hydroxy succinimide (NHS) esters of TAM and Cy5.

Figure 6: Synthetic schemes to prepare Fam-proline, Azido-proline and Cy5-phosphine. TMSCl = trimethylsilyl chloride.

Figure 7: The eight unique fluorescence signatures of CFET tags generated in a three-color CAE system. FAM channel ( $520 \pm 20$  nm, dotted line), TAM channel ( $585 \pm 20$  nm, solid thin line), Cy5 channel ( $670 \pm 20$  nm, solid thick line). The digital ratio denoting the fluorescence signature for each CFET tag from the three channels [dotted:thin:thick] is shown in the brackets. The fluorescence signatures in the electropherogram were obtained by excitation at 488 nm and electrokinetic injection of the eight CFET-labeled oligonucleotides into the three-color CAE system.

Figure 8A-B: Schematic of using ligase chain reaction for determining the genotype at a locus containing a possible single-base mutation.

5 (A) Primer pairs are generated surrounding a base that can be mutated. The wild-type primer is labeled with one CFET tag (Tag 1) and the mutation-specific primer with another CFET tag (Tag 2).

10 (B) Subsequent gel electrophoresis allows separation of ligated primer pairs and unincorporated primers. Different bands appear on the gel depending on whether the template is wild-type or mutated.

15 Figure 9: Schematic of expected results from screening four potential mutation sites of Rb1 gene using eight unique CFET Tags and the ligase chain reaction assay. Only ligation products are shown on the gels.

20

Figure 10: Schematic of chromosomal studies to detect macrodeletions and amplifications.

25 Figure 11: This figure schematically shows the procedure for multiplex SNP detection through the ligation of hybridized CFET-labeled and biotinylated oligonucleotides. Taq DNA ligase seals the nick between the two hybridized oligonucleotides if the nucleotides at the ligating junction are correctly base-paired to the template (A to T; C to G). CFET-labeled, biotinylated ligation products are then  
30 isolated using streptavidin-coated magnetic beads. After washing and releasing from the magnetic beads,

the ligation products are electrokinetically injected into a three-color CAE system. Each CFET-labeled ligation product, which identifies a unique SNP, is unambiguously detected due to its distinct mobility and fluorescence signature in the CAE electropherogram.

Figure 12A-B: Electropherogram of CFET-labeled ligation products for SNPs identification on exon 20 of the RB1. (A) Detection of six nucleotide variations from synthetic DNA templates. FAM (T) and F-10-Cy5 (T) peaks are obtained from two different locations of the same template. F-9-T (C) and F-13-T (T) peaks indicate mutations from the same locus of a DNA template, while F-4-T-6-Cy5 (A) and F-7-T-7-Cy5 (C) peaks identify mutations from the same locus of another DNA template. (B) Detection of three homozygous genotypes (T, C and A) from a PCR product of RB1.

Figure 13: This figure is a schematic of single base primer extension for multiplex SNP detection by using dye-labeled primers and biotinylated dideoxynucleoside triphosphates (ddNTP-Biotin). DNA template containing polymorphic sites is incubated with a dye-labeled primer, hybridizing the template adjacent to the polymorphic site, ddNTP-Biotin and thermo sequenase. At the end of reaction and purification the primer extension products are analyzed for fluorescence signatures.

Figure 14: Three unique fluorescence signatures generated from dye-labeled extension products. FAM

channel (light) and TAM channel (Dark). The fluorescence signatures in the electropherograms were obtained by excitation at 488nm and the single base extension of the dye-labeled primers. The digital ratio denoting the fluorescence signature for each from the two detection channels is shown in parentheses.

Figure 15A-C: The electropherograms of CFET-labeled primer extension products for multiplex SNPs identification on the mimic of exon 20 of the RB1. FAM channel (Light line) and TAM channel (Dark line). (A): Detection of two individual homozygous genotypes from a wild type template. FAM (T) and F-9-T (C) peaks were obtained from two different loci on the template. (B): Similar to (A) except a mutated template was used. (C): Simultaneous detection of three nucleotide variations. FAM (T) peak was obtained from a locus of the template where a homozygous genotype was found. F-9-T (C) and F-13-T (T) peaks indicate the mutation R661W (heterozygote) from the same locus of a DNA template.

Figure 16: Schematic of a high throughput channel based, moiety-based purification system. Sample solutions can be pushed back and forth between the two plates through glass capillaries and the coated channels in the chip, the channels being coated with an appropriate chemical to bind the moiety tag on the samples, e.g. streptavidin coating in the case of biotinylated oligonucleotides. Where the moieties are attached by cleavable linkers, e.g. photocleavable

linkers, the whole chip can be irradiated to cleave the samples after immobilization.

Detailed Description Of The InventionDefinitions

5 The following definitions are offered as an aid to understanding the invention:

	CAE	-	Capillary Array Electrophoresis
	CFET	-	Combinatorial fluorescence energy transfer;
10	Cy 5	-	Cyanine 5 monofunctional dye;
	ddNTP	-	Dideoxynucleotide trisphosphate;
	FAM	-	6-carboxyfluorescein;
	nm	-	nanometer
	RB1	-	Retinoblastoma gene;
15	SNP	-	Single nucleotide polymorphism;
	TAM	-	N,N,N',N'-tetramethyl-6-carboxy rhodamine.

20 As used herein, and unless stated otherwise, each of the following terms shall have the definition set forth below.

25 "Chemically cleavable" shall mean cleavable by any chemical means including but not limited to pH and temperature.

"DNA/RNA" shall mean a nucleic acid molecule comprising both deoxyribonucleotides and ribonucleotides.

30 "Emission spectrum" shall mean the amplitude and frequency of energy emitted from a composition of matter as a result of exciting radiation thereon.



"Flexible", when used to describe a molecular scaffold, shall mean that the distance between the centers of any pair of fluorophores covalently bound to the scaffold varies by more than 50%.

"Fluorescence energy transfer" shall mean the transfer of energy between two fluorophores via a dipole-dipole interaction.

10

"Fluorescent dye" shall mean an organic dye molecule capable of emitting fluorescent energy of wavelength between 200 and 1000nm when excited by an energy of shorter wavelength wherein the emitted energy results from a singlet to singlet transition. Examples are 6-carboxyfluorescein, N,N,N',N'-tetramethyl-6-carboxyrhodamine, and cyanine-5 monofunctional dye.

15

"Fluorophore" shall mean a molecule, such as a fluorescent dye, quantum dot or luminescent molecule, capable of emitting energy of wavelength between 400 and 1000nm when excited by an energy of shorter wavelength than the corresponding emission wavelength. Examples of fluorophores include 6-carboxyfluorescein, N,N,N',N'-tetramethyl-6-carboxy rhodamine, cyanine-5 monofunctional dye, zinc sulfide-capped cadmium selenide quantum dots, and lanthanide chelates.

20

25

"Hybridize" shall mean the annealing of one single-stranded nucleic acid molecule to another single stranded nucleic acid molecule based on sequence complementarity. The propensity for hybridization

30


between nucleic acids depends on the temperature and ionic strength of their milieu, the length of the nucleic acids and the degree of complementarity. The effect of these parameters on hybridization is well known in the art (see Sambrook, 1989).

"Isolation-permitting moieties" shall include without limitation biotin or streptavidin which bind to one another, antibodies or antigens which bind to one another, phenylboronic acid or salicylhydroxamic acid which bind to one another.

"Ligation-permitting conditions" include without limitation conditions of temperature, ionic strength, ionic composition, molecular composition, orientation and viscosity that allow one oligonucleotide to be joined enzymatically to another via a phosphodiester bond.

"Ligation" shall mean the enzymatic covalent joining of a nucleic acid with either another nucleic acid or a single nucleotide.

"Linker molecule" shall mean a chemical group used to covalently join two other molecules. An example of a linker molecule is the structure given below:



"Luminescent molecule" shall mean a molecule capable of emitting energy of wavelength between 200 and 1000nm when excited by energy of shorter wavelength than the corresponding emission wavelength, wherein the emitted energy does not result from a singlet to singlet transition. Examples of luminescent molecules include europium polycarboxylate chelate and terbium chelates.

"Molecular scaffold" shall mean a molecular structure to which two or more fluorophores can be, and/or are, covalently bound at discrete loci thereon. Ideally, a molecular scaffold is polymeric, comprising monomeric units to which fluorophores can be bound. The monomeric units which make up such polymeric scaffold can, but need not be, identical. Examples of such monomeric units include 1',2'-dideoxyribose phosphate and thymidine.

"Nucleic acid molecule" shall mean any nucleic acid molecule, including, without limitation, DNA, RNA and hybrids thereof. The nucleic acid bases that form nucleic acid molecules can be the bases A, C, G, T and U, as well as derivatives thereof. Derivatives of these bases are well known in the art, and are exemplified in PCR Systems, Reagents and Consumables (Perkin Elmer Catalogue 1996-1997, Roche Molecular Systems, Inc., Branchburg, New Jersey, USA).

"Oligonucleotide" shall mean a nucleic acid comprising two or more nucleotides.

"Photocleavable" shall mean cleavable by electromagnetic energy of between 200 and 1000nm wavelength.

5 "Polymeric" shall describe a molecule composed of more than two monomeric units.

10 "Quantum dot" shall mean a nanometer-sized composition of matter comprising a semi-conductor or metal, wherein such composition is capable of luminescence. Examples of quantum dots include zinc-sulfide-capped cadmium selenide quantum dots.

15 "Rigid", when used to describe a molecular scaffold, shall mean that the distance between the centers of any pair of fluorophores covalently bound to the scaffold does not vary more than 50%.

#### Embodiments of the Invention

20

This invention provides a composition of matter comprising multiple fluorophores, each of which is bound to a molecular scaffold at a separate predetermined position on the scaffold, such separate  
25 predetermined positions being selected so as to permit fluorescence energy transfer between one such fluorophore and another such fluorophore, wherein the one such fluorophore and the another such fluorophore are characterized by the maximum emission wavelength  
30 of one being greater than the minimum excitation wavelength of the other.

This invention further provides the instant

composition of matter comprising two fluorophores,  
each of which is bound to a molecular scaffold, at a  
separate predetermined position on the scaffold, such  
separate positions being selected so as to permit  
5 fluorescence energy transfer between such  
fluorophores, and such fluorophores being  
characterized by the maximum emission wavelength of  
one of the fluorophores being greater than the  
minimum excitation wavelength of the other  
10 fluorophore.

This invention further provides the instant  
composition of matter comprising three fluorophores  
each of which is bound to a molecular scaffold at a  
15 separate predetermined position on the scaffold, such  
separate predetermined positions being selected so as  
to permit fluorescence energy transfer among such  
fluorophores and such fluorophores being  
characterized by the maximum emission wavelength of  
20 one such fluorophore being greater than the minimum  
excitation wavelength of the second such fluorophore  
and the maximum emission wavelength of such second  
fluorophore being greater than the minimum excitation  
wavelength of the third such fluorophore.

25

In one embodiment each fluorophore is covalently  
bound to the molecular scaffold.

30

In one embodiment the efficiency of the fluorescence  
energy transfer is less than 20%.

In one embodiment the molecular scaffold is rigid.

In one embodiment the molecular scaffold is polymeric.

5

In one embodiment the molecular scaffold comprises a nucleic acid.

10

In one embodiment the molecular scaffold comprises a peptide.

In one embodiment the molecular scaffold comprises a polyphosphate.

15

In one embodiment at least one fluorophore is a fluorescent dye.

20

In one embodiment the fluorescent dye is 6-carboxyfluorescein.

In one embodiment the fluorescent dye is N,N,N',N'-tetramethyl-6-carboxyrhodamine.

25


In one embodiment the fluorescent dye is cyanine-5 monofunctional dye.

In one embodiment at least one fluorophore is a luminescent molecule.

30

In one embodiment at least one fluorophore is a quantum dot.

This invention also provides a composition of matter having the structure:



5

10

15


wherein S represents a 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, each T represents a thymidine derivative, FAM represents 6-carboxyfluorescein derivative, TAM represents N,N,N',N'-tetramethyl-6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q are different.

20

In one embodiment m is 4. In one embodiment m is 6. In one embodiment m is 9. In one embodiment m is 13.

This invention also provides a composition of matter having the structure:

25




30

wherein S represents a 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, T represents a thymidine

derivative, FAM represents a 6-carboxyfluorescein derivative, Cy5 represents a cyanine-5 monofunctional dye derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q are different.

In one embodiment m is 4. In one embodiment m is 5. In one embodiment n m is 7. In one embodiment m is 10. In one embodiment m is 13.

This invention also provides a composition of matter comprising the structure shown below:




wherein S represents a 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, n is an integer greater than 1 and less than 100, T represents a thymidine derivative, FAM represents a 6-carboxyfluorescein derivative, Cy5 represents a cyanine-5 monofunctional dye derivative, TAM represents a N,N,N',N'-tetramethyl-6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q are different.



In one embodiment m is 3, and n is 7. In one  
embodiment, wherein m is 4, and n is 6. In one  
embodiment m is 5, and n is 5. In one embodiment m is  
5 6, and n is 6. In one embodiment m is 7, and n is 7.

This invention also provides a composition of matter  
comprising the structure shown below:

10



15

wherein S represents a 1',2'-dideoxyribose  
phosphate moiety, m represents an integer greater  
than 1 and less than 100, T represents a  
thymidine derivative, and TAM represents a  
20 N,N,N',N'-tetramethyl-6-carboxyrhodamine  
derivative, each solid line represents a covalent  
bond, R represents either a hydroxy or phosphate  
terminus and Q represents either a hydroxy or  
phosphate terminus, with the proviso that R and Q  
25 are different.

In one embodiment m is 4.

This invention also provides a nucleic acid labeled  
30 with any of the instant compositions.

In one embodiment the nucleic acid is DNA.

In one embodiment the nucleic acid is RNA.

In one embodiment the nucleic acid is DNA/RNA.

5 This invention also provides a method of determining whether a preselected nucleotide residue is present at a predetermined position within a nucleic acid comprising the steps of:

10 (a) contacting the nucleic acid, under hybridizing and DNA ligation-permitting conditions, with (i) a DNA ligase, (ii) a first oligonucleotide having affixed thereto a composition of matter of claim 1 wherein the first oligonucleotide  
15 hybridizes with nucleotides immediately adjacent one side of the predetermined position and (iii) a second oligonucleotide which hybridizes with the nucleotides immediately adjacent the other side of the  
20 predetermined position, wherein the hydroxy-terminal residue of the oligonucleotide which hybridizes to the nucleotide located 3' of the predetermined position is a nucleotide which is  
25 complementary to the preselected nucleotide residue; and

(b) detecting the presence of a ligation product comprising both the first and the second oligonucleotides, the presence of  
30 such a ligation product indicating the presence of the preselected nucleotide residue at the predetermined position.

This invention further provides a method of determining whether at various predetermined positions within a nucleic acid, a preselected nucleotide residue is present at such position, wherein the preselected nucleotide residue may vary at different predetermined positions which comprises determining whether each preselected nucleotide is present each predetermined position according to the instant method.

10

In one embodiment the presence of a plurality of given nucleotide residues is determined simultaneously.

15

In one embodiment the DNA ligase is Taq DNA ligase.

20

This invention further provides the instant method, wherein the second oligonucleotide has an isolation-permitting moiety affixed thereto, and wherein the method further comprises the steps of isolating the moiety-containing molecules resulting from step (a) and determining the presence therein of ligated first and second oligonucleotides.

25

30

This invention further provides the instant method, wherein the composition of matter affixed to the first oligonucleotide has a predetermined emission spectrum, and wherein the observation of this emission spectrum is employed to determine the presence of ligated first and second oligonucleotides in step (b).

This invention also provides a method of determining whether a preselected nucleotide residue is present at a predetermined position within a nucleic acid comprising the steps of:

- 5 (a) contacting the nucleic acid, under hybridizing and DNA polymerization-permitting conditions, with (i) a DNA polymerase, (ii) an oligonucleotide (1) having affixed thereto a composition of matter of claim 1, and (2) having  
10 a hydroxyl 3' terminus thereof, wherein the oligonucleotide hybridizes with the 3' region of the nucleic acid molecule flanking the predetermined position, and (iii) a dideoxynucleotide labeled with an isolation-permitting moiety, wherein the labeled  
15 dideoxynucleotide is complementary to the given nucleotide residue, with the proviso that upon hybridization of the oligonucleotide with the nucleic acid in the presence of DNA polymerase and the preselected  
20 nucleotide residue, the oligonucleotide and dideoxynucleotide are juxtaposed so as to permit their covalent linkage by the DNA polymerase;
- (b) detecting the presence of a polymerization  
25 product comprising both the oligonucleotide and the dideoxynucleotide, the presence of such a polymerization product indicating the presence of the preselected nucleotide residue at the predetermined position.

30

This invention further provides a method of determining whether at various predetermined positions within a nucleic acid, a preselected

5 nucleotide residue is present at such position, wherein the preselected nucleotide residue may vary at different predetermined positions which comprises determining whether each preselected nucleotide is present each predetermined position according to the instant method.

10 In one embodiment the DNA polymerase is thermostable.

This invention further provides the instant method, wherein the dideoxynucleotide is selected from the group consisting of dideoxyadenosine triphosphate, dideoxycytidine triphosphate, dideoxyguanosine triphosphate, dideoxythymidine triphosphate, and dideoxyuridine triphosphate.

20 This invention further provides the instant method, wherein the composition of matter affixed to the oligonucleotide has a predetermined emission spectrum, and wherein the observation of this emission spectrum is employed to determine the presence of polymerization product in step (b).

25 This invention further provides the instant methods, wherein observing the predetermined emission spectrum is performed using radiation having a wavelength of between 200 and 1000nm.

30 In one embodiment the radiation has a wavelength of 488 nm.

This invention further provides the instant methods, wherein observing the predetermined emission spectrum is performed using radiation having a bandwidth of between 1 and 50nm.

5

In one embodiment the radiation bandwidth is 1nm.

This invention further provides the instant methods, wherein the isolation-permitting moiety comprises  
10 biotin, streptavidin, phenylboronic acid, salicylhydroxamic acid, an antibody or an antigen.

This invention further provides the instant methods, wherein the isolation-permitting moiety is attached  
15 to the oligonucleotide via a linker molecule.

This invention further provides the instant methods, wherein the isolation-permitting moiety is attached to the dideoxynucleotide via a linker molecule.


20

This invention further provides the instant methods, wherein the linker molecule is chemically cleavable.

This invention further provides the instant methods, wherein the linker molecule is photocleavable.  
25

This invention further provides the instant methods, wherein the linker molecule has the structure:

30



This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.

## Experimental Details

### I. The Design of Combinatorial Fluorescence Energy Transfer Tags

5

Background: Optical interactions persist between two chromophores even when they are as far as 80 angstroms apart. The chromophore with high energy absorption is defined as a donor, and the chromophore with lower energy absorption is defined as an acceptor. Fluorescence energy transfer is mediated by a dipole-dipole coupling between the chromophores that results in resonance transfer of excitation energy from an excited donor molecule to an acceptor (Förster, 1965). Förster established that the energy transfer efficiency is proportional to the inverse of the sixth power of the distance between the two chromophores. Fluorescence resonance energy transfer has been used extensively as a spectroscopic ruler for biological structures (Stryer, 1978), and energy transfer-coupled tandem phycobiliprotein conjugates have found wide applications as unique fluorescent labels (Glazer and Stryer, 1983). A set of polycationic heterodimeric fluorophores that exploit energy transfer and have high affinities for double-stranded DNA were also developed, offering advantages over monomeric fluorophores in multiplex fluorescence labeling applications (Benson et al., 1993; Rye et al., 1993). By exploiting fluorescence energy transfer principle, using a common donor and four different acceptors, four sets of ET primers and dideoxynucleotides were constructed that are markedly superior to single dye labels in DNA sequencing, and

30



in multiplex polymerase chain reaction (PCR)-based mapping and sizing protocols (Ju et al., 1995, 1996).





















5 The present application discloses how energy transfer and combinatorial concepts can be used to tune the fluorescence emission signature of fluorescent tags for the development of a large number of combinatorial fluorescence energy transfer (CFET) tags. A schematic construction of the tags is shown  
10 in Figure 1a. Representative examples for the construction of the CFET tags and their expected fluorescence signatures are shown in Table 1. Three individual fluorescent dyes, 6-carboxyfluorescein (FAM or F), N,N,N',N'-tetramethyl-6-carboxyrhodamine  
15 (TAM or T) and Cyanine dye (Cy5 or C) are selected as examples to construct the CFET tags. The fluorescence emission maxima for FAM, TAM and Cy5 are 525nm, 580nm and 670nm, respectively. Chemical moieties used as spacers are selected to construct  
20 various CFET tags aimed at conveniently labeling biomolecules and other targets of interest, monomers are convenient to employ. Other spacer moieties include nucleotides, peptides and 1'2'-dideoxyribose phosphates. As shown in Table 1, tag 1 is constructed  
25 with FAM alone and displays its characteristic fluorescence signature ( $\lambda_{\text{max}} = 525 \text{ nm}$ ). Any fluorophore with a characteristic fluorescence signature could be used in place of FAM. With FAM as a donor and TAM as an acceptor, CFET tags 2, 3, 4,  
30 and 5 can be constructed by changing the distance "R" between the FAM and TAM chromophores. The rationale is that altering the distance between donor and acceptor changes the energy transfer efficiency, and

therefore the ratio of the fluorescence emission intensity of the donor (FAM) and acceptor (TAM).

Similarly, with FAM as a donor and Cy5 as an acceptor, CFET tags 6, 7 and 8 can be generated.

- 5 With three dyes, with FAM as a donor, TAM as an acceptor for FAM and as a donor for

Table 1 Representative Example of CFET Tags

CFET Tag	Fluorescence Signature	Tag ID
		1
		2
		3
		4
		5
		6
		7
		8
		9
		10

Cy5, which acts as the final acceptor, CFET tags 9 and 10 can be constructed by manipulating distances "R1" and "R2". All the CFET tags can be excited with a single laser source and analyzed by simple detectors capable of capturing the emission signatures from each tag. In other embodiments, more than three dyes can be used. Alternatively just single chromophores can be used as long as they have unique fluorescence signatures.

10

The donor and acceptor fluorescent molecules are separated using convenient chemical moieties as spacers to tune the fluorescence signatures of the CFET tags. Examples of such spacer moieties include nucleotides, dideoxyribose phosphate, and amino acids. The construction of CFET tags involving three or more different dyes is more challenging, since synthetic procedures need to be designed for introducing the individual dye molecules at specific locations on the spacing backbone. As an example, CFET tags involving three dyes can be constructed using oligonucleotides as spacers. An oligonucleotide with the sequence 5'-TTTTTTTTTTTTTTTTTTTTTC-3' (SEQ ID NO: 1) was selected as a scaffold to covalently attach FAM, TAM and Cy5. FAM is introduced by using a 6-FAM-dT phosphoramidite, TAM is introduced by using TAM-dT (Glen Research, Sterling, VA), and a modified T having an amino linker at the C-5 position (Glen Research) is incorporated into the oligonucleotide which is then linked to Cy5 - N-Hydroxy succinimide (NHS) ester. The final product is purified by size exclusion chromatography and gel electrophoresis. A

representative reaction for the construction of CFET tag F-4-T-6-C (the numbers refer to the number of spacing nucleotides) involving FAM, TAM and Cy5 is shown in Figure 1. By changing the spacing between FAM and TAM, and TAM and Cy5, two CFET tags F-4-T-6-C and F-7-T-3-C with the fluorescence signatures corresponding to tags 9 and 10 have been constructed as shown in Figure 2. Shown are the ultraviolet/visible absorption spectrum of F-4-T-6-C (Figure 2B) as well as the fluorescence emission spectra for F-4-T-6-C and F-7-T-3-C (Figures 2C and 2D), with excitation at 488 nm (1x Tris-Borate-Ethylenediaminetetraacetic acid (TBE) solution). The UV/visible spectrum exhibits the characteristic absorption of FAM at 495 nm, TAM at 555 nm and Cy5 at 649 nm (Figure 2B). The fluorescence emission spectrum of F-4-T-6-C displays a fluorescence signature with Cy5 highest, TAM next and FAM lowest; whereas F-7-T-3-C displays a fluorescence signature with FAM highest, TAM next and Cy5 lowest. The two fluorescence signatures are clearly different, and easily discernible by spectroscopic methods. Here the feasibility of the CFET approach involving three different dyes is clearly demonstrated.

It is evident that one can synthesize broad families of CFET tags. Examples of two synthetic approaches for constructing CFET tags are shown: (1) 1',2'-dideoxyribose phosphate monomer can be used as a spacer to separate dyes used for labeling oligonucleotide primers, which can be assembled on a DNA synthesizer; (2) a rigid peptide linker can be

used to construct a CFET cassette to label any other molecular targets.

The first example is shown in Figure 3A. A polymer  
5 linker (SSS...SSSS) formed by 1',2'-dideoxyribose  
phosphates (S) at the 5' end of the desired primer  
sequence forms a universal spacer for attaching the  
ET-coupled fluorophores, thereby producing an ET  
cassette. The 1',2'-dideoxyribose phosphates can be  
10 introduced using 5'-dimethoxytrityl-1',2'-  
dideoxyribose-3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-  
phosphoramidite (dSpacer CE Phosphoramidite, Glen  
Research, Sterling, VA). dSpacer CE Phosphoramidite  
has previously been used to construct DNA sequencing  
15 primers (Ju et al., 1996). In this CFET tag  
construction, FAM is used as a common donor. In a  
CFET tag consisting of two different fluorescent  
dyes, either TAM or Cy5 can be used as acceptors;  
whereas in a CFET tag consisting of three different  
20 fluorescent dyes, TAM can also be used as a donor for  
Cy5. The length of the spacing between each  
donor/acceptor pair can be changed systematically to  
achieve the expected fluorescence signatures as shown  
in Table 1. FAM and TAM can be introduced using  
25 phosphoramidite FAM-dT and TAM-dT and Cy5 can be  
introduced to the modified T carrying an amino linker  
as described above. The use of such spacers is  
advantageous in several aspects: (i) the spacer will  
not hybridize to any sequences within the DNA  
30 template and therefore false priming is avoided; (ii)  
the linkage of the spacer maintains the natural  
nucleic acid phosphate functionality, which avoids  
possible anomalies in electrophoretic mobility; and

(iii) the elimination of the aromatic base groups on the deoxyribose rings in the spacer may reduce the likelihood of fluorescence quenching.

5 The second synthetic approach requires sophisticated selective synthetic chemistry procedures for the CFET tag construction. As an example, Figure 3B shows a general scheme for the construction of CFET-deoxyuridine triphosphate (dUTP) using poly-proline  
10 (P) peptide as a spacer. The spacing between each donor/acceptor pair can be changed systematically to achieve the expected fluorescence signatures as shown in Table 1. Figure 4 shows a scheme for the synthesis of CFET-dUTP consisting of Fam, Tam and  
15 Cy5. Peptide synthesis procedure using tert-butylcarbonyl (t-Boc) chemistry is employed on a peptide synthesizer to construct the scaffold of the desired molecules. Starting with a glycine-resin as C-terminal, a modified proline tagged with FAM (Fam-proline)  
20 is coupled to glycine, then proline monomers are added, followed by reacting with another modified proline that has a protected primary amino linker (TFA-NH-proline) for the subsequent incorporation of Tam. Next, proline spacer is again added, followed  
25 by reacting with the azido-proline for the subsequent incorporation of Cy5. After cleavage from the resin and removal of the trifluoroacetyl group, compound 1 in Figure 4 is obtained. Compound 1 reacts with TAM-NHS ester to form compound 2, which will then react  
30 with Cy5-phosphine (3) to produce compound 4, which has all the three dyes incorporated. Cy5-phosphine (3) can be synthesized using the modified Staudinger reaction developed by Bertozzi (Saxon and Bertozzi,

2000). Conversion of compound 4 to an NHS ester produces 5, which is then coupled to Aminoallyl (AA)-dUTP (Sigma) to generate the final product CFET-dUTP. By varying the number of proline spacers between Fam and Tam, and between Tam and Cy5, a library of CFET-dUTPs with unique fluorescence signatures can be developed. The intermediates 2, 4, 5, and the final products can be purified by high pressure liquid chromatography (HPLC), size exclusion chromatography and gel electrophoresis. The structures of AA-dUTP, Fam-Proline, and NHS esters of TAM and Cy5 are shown in Figure 5. Brief synthetic schemes for the synthesis of trifluoroacetic (TFA) - NH-proline, Fam-proline, azido-proline and Cy5-phosphine are shown in Figure 6. Unique fluorescence signatures for 8 synthesized CFET tags are shown in Figure 7.

## II. Biomedical Applications of Combinatorial Fluorescence Energy Transfer Tags

The ability to sequence DNA accurately and rapidly is revolutionizing biology and medicine. The confluence of the massive Human Genome Project is driving an exponential growth in the development of high throughput genetic analysis technologies. This rapid technological development involving biology, chemistry, computer science, and engineering makes it possible to move from studying genes one by one to approaches which can analyze and compare entire genomes.

Sophisticated techniques have enabled large-scale dissection of genomes. For instance, the development



of cloning vectors which can maintain and reproduce large stretches of DNA (up to a million bases) has resulted in clone libraries which span most of the chromosomes from end to end for many of the highly studied organisms including humans - so-called physical maps. Recognizing sequence markers that differ from one individual to another across the human genome has permitted them to be followed in families that harbor genetic diseases. If a marker cosegregates with the disease phenotype, one can be assured that the marker is in the vicinity of the gene responsible for that disease. Automated sequencing methods have made it possible to obtain the complete chemical composition of the genome with unprecedented speed, and computational approaches are beginning to allow annotation of these sequences, identification of the genes and other elements that comprise the chromosomes. Gene expression has moved from the arena of analyzing a few genes at a time by the techniques of Northern blot analysis, to creating vast microarrays of these genes on glass slides or silicon chips (Schena et al. 1995, Chee et al. 1996). Methods for identifying single nucleotide polymorphisms (SNPs) (Chen and Kwok, 1997), DNA-protein and protein-protein interactions (Uetz et al. 2000), and members of metabolic, signal transduction and other pathways are also being developed. All these advances will have the potential to revolutionize medical and clinical research in establishing diagnostic, prognostic or treatment options.

It is noteworthy that many of the genomic techniques mentioned have benefited from the use of novel molecular tags, especially fluorescent dye molecules. DNA sequencing serves as a good example for  
5 evaluating the impact of this technology. Although the ability to obtain DNA sequences originated in the late 1970's with the development of the chemical cleavage approach of Maxam and Gilbert (1977) and the dideoxynucleotide terminator approach of Sanger et  
10 al. (1977), it was the latter that was most amenable to automation and fluorescent labeling strategies. In the past 15 years, in rapid succession, the ability to use four dyes in a single sequencing lane, one for each of the four bases in DNA (Smith et al.  
15 1986), the ability to use cycle sequencing with heat stable enzymes (Tabor et al. 1995), the development of energy transfer dyes which produced higher signals (Ju et al., 1995; Lee et al., 1997), and more recently, the ability to obtain long sequence reads  
20 in separate capillary tubes instead of adjacent lanes on polyacrylamide slab gels, has made sequencing increasingly robust. Future improvements in sequencing technology, including miniaturization and solid phase approaches, will continue to take  
25 advantage of energy transfer (ET) and other novel fluorescent tags (Ju et al., 1997). Investigators are also utilizing ET dyes for investigating gene expression on microarrays (Hacia et al. 1998). All of these approaches are believed to be limited to  
30 single pairs of donor and acceptor dyes for each reaction. The CFET approach described herein whereby one, two or more dyes, disposed at varying molecular distances from each other to generate many

alternative discrete signatures offers the possibility of obtaining an order of magnitude higher throughput in many of these genomic approaches. Genetic mutation and chromosome analysis are two  
5 examples of the biomedical application of these CFET tags. Using CFET tags in combination with single fluorophore tags, and/or multiple dye tags where no FET occurs, the number of possible unique fluorescence signatures, and hence the number of e.g.  
10 SNPs detectable simultaneously, is hugely increased.

Gene mutations play important roles in the development of many human diseases. It has become increasingly apparent that missense mutations (single  
15 base changes usually culminating in amino acid changes or introduction of stop codons which lead to truncated proteins), microdeletions and microinsertions (both of which can change the reading frame and also usually lead to protein truncation)  
20 can occur at many positions along the length of the responsible gene. A number of studies have sought to identify causative mutations and predisposing polymorphisms for a number of cancers and other diseases. These include chronic lymphocytic leukemia  
25 and other blood cancers (Kalachikov et al. 1997; Qu et al. 1998), the long QT syndrome (an ionic disturbance in the heart visible on electrocardiograms and an important risk factor for sudden cardiac death), breast cancer (Fischer et al.  
30 1996), the rare ICF syndrome (immune deficiency/centromeric instability/facial anomalies) (Xu et al. 1999), and more recently such complex disorders such as asthma and diabetes.

With the exception of the types of small mutations described above and single nucleotide polymorphisms that occur, on average, every 1000 nucleotides, the 6 billion nucleotide pairs that make up the diploid human genome are largely identical from individual to individual. Nonetheless, large deletions, amplifications and rearrangements do occur, and such chromosomal anomalies are often associated with serious and life-threatening diseases. The best known example is probably the third copy of chromosome 21 in individuals with Down syndrome, but many other chromosomal translocations and macrodeletions are associated with cancer and other disease syndromes. If one is able to mark the positions along chromosomes with identifiable "color-coded" probes, it should be possible to easily detect such large-scale changes in chromosomal geography. In fact, the field of chromosome painting (multicolor fluorescence *in situ* hybridization (M-FISH) has been used for just such analyses (Speicher et al. 1996). A larger set of more readily separable CFET tag signatures might greatly aid in this enterprise. The established chromosome painting techniques require appropriate mixing of the different dyes prior to labeling, and so are used almost exclusively for labeling whole chromosomes.

### III. CFET Tags for Multiplex Gene Mutation Detection Using Ligase Chain Reaction

Ligase chain reaction (LCR) is a procedure for genetic mutation analysis using ligase and a pair of

oligonucleotides (Eggerding, 1995; Wu and Wallace, 1989; Landegren et al., 1988). Briefly, it is based on the fact that two adjacent oligonucleotides can only be ligated if the adjoining bases are complementary to the template strand. If there is a single base difference within two bases of the join site, ligation will not occur. Pairs of oligonucleotides are designed spanning the ligation site on the template DNA, including one harboring either the wild-type or mutated base. In the usual procedure, one of the oligonucleotides is radiolabeled at the phosphate group at its 5' end. Following the ligase chain reaction, which involves multiple rounds of denaturing, primer annealing and ligation, one can separate the products from the substrates on polyacrylamide gels. The procedure can be modified using single stranded DNA template as shown in Figure 8 for testing using the CFET tags. Primer pairs are generated surrounding a base that can be mutated. For example, the template may contain a T (wild-type, wt) or C (mutated, mut) at the relevant position. The wt primers are complementary to the wt template at every position. The primer on the right side of Figure 8A is labeled with CFET tag 1 to yield a specific fluorescent signature. The mutation-specific primer, two bases longer than its wild-type analog, is complementary to every position of the mutated template. This primer is labeled with CFET tag 2 displaying another unique fluorescent signature. A common 20 base pair primer will be used on the other side of the ligation site. In cases where ligation does not occur, because a wild-type oligonucleotide was used with a mutated

template sequence, or a mutated oligonucleotide was used with a wild-type template sequence, the only fluorescent band on the acrylamide gel will be the size of the tagged primer. In contrast, if there is no mismatch at the ligation junction, two fluorescent bands, one the size of the primer and one the size of the joined primers will form. Following ligase chain reaction, the left and right primer will be ligated only if they are completely complementary to the template. Thus, with a wt template, only a 40 base product will result, and only a 42 base product will result from a mut template as shown in Figure 8B. By virtue of the unique fluorescence emission signatures of the CFET tags, it is possible to display the products of several mutation positions simultaneously, each labeled with a different CFET Tag. The ligated products can be separated and analyzed in a single gel lane. In order to accomplish this, the multiplex set of oligonucleotides that contain the potentially mutated position can be 5'-end labeled, each with a specific CFET tag. For example, one can test four different mutation sites using eight distinct CFET tags.

As shown in Table 2, eight primers labeled with eight unique CFET tags (1, 2, 3, 4, 5, 6, 9, and 10 of Table 1) can be constructed as shown in the general labeling scheme in Figure 3A using 1',2'-dideoxysugar phosphate (S) as spacers. For this set of CFET tag constructs, FAM is used as a common donor, and TAM and/or Cy5 as acceptors. The length of the spacing between each donor/acceptor pair,  $(S)_m$  and  $(S)_n$ , can be changed systematically to achieve the expected

fluorescence signatures as depicted in Table 1. FAM and TAM can be introduced using FAM-dT and TAM-dT phosphoramidites and Cy5 can be introduced to the modified T carrying an amino linker as described above.

The system can be tested, for example, by synthesizing single stranded DNA templates mimicking known single base mutations in exon 20 of the retinoblastoma susceptibility (RB1) gene (Schubert et al. 1994, Lohmann 1999). The sequences of two sets of synthetic templates (wt and mut) which can be used in the analysis are shown in Table 3. The sequence of the potential mutation positions is shown in bold-face as "A", "C", "G" and "T". Primer sets 1 and 2 in Table 2 are used for the testing of both wild type and mutated base positions of Template A, respectively; while primer sets 3 and 4 are for testing both wild type and mutated base positions of Template B, respectively. To maximize the number of samples that can be detected on a polyacrylamide gel, the primers surrounding each "mutated" position can be designed to be a unique length as shown in Figure 9. For example, the two CFET labeled oligonucleotides (one for the wild-type gene and one for the mutated gene) surrounding mutation position 1 are 20 and 22 bases long, respectively, and the unlabeled common primer is 20 bases long. Any resulting ligation product will be either 40 or 42 bases long. Likewise, for mutation position 2, 24 and 26 base labeled oligonucleotides can be constructed, as well as a different 20 base common primer, leading to ligation products of either 44 or 46 bases. More

primers can, of course, be generated by making the sizing increment one base instead of two bases for each different mutation, or creating a second set of labeled primers whose ligation products run between 80 and 98 base pairs, between 120 and 138 base pairs, etc. Since single base pair resolution up to the length of ~ 400 bp DNA fragments is easily achieved in polyacrylamide gel electrophoresis, the ligated products can be readily resolved in such standard fluorescent gel systems. Furthermore, the advantage of being able to clearly distinguish the products based on their fluorescent signatures, as well as size, makes this assay extremely powerful. Expected gel electrophoresis results for this multiplex testing system are shown on the right side of Figure 9. Here, template collection 1 is seen to contain only wt sequences. In contrast, template pool 2 contains one template with a mutation at position 2 and a heterozygote genotype at position 4.



Table 2. Eight primers used for multiplex mutation detection

5	Primer 1L:	3'-ttaaaaagaataagggtgtc-5' (SEQ ID NO: 2)
	Primer 1R wt:	3'-Acatagccgatcggatagag-5'-CFET1 (SEQ ID NO: 3)
10	Primer 1R mut:	3'-Tcatagccgatcggatagaggc-5'-CFET2 (SEQ ID NO: 4)
	Primer 2L:	3'-acatagccgatcggatagag-5' (SEQ ID NO: 5)
15	Primer 2R wt:	3'-Gccgatttatgtgaaacacttgcg-5'-CFET3 (SEQ ID NO: 6)
	Primer 2R mut:	3'-Accgatttatgtgaaacacttgcgga-5'-CFET4 (SEQ ID NO: 7)
20	Primer 3L:	3'-cggaagacagactcgtgggt-5' (SEQ ID NO: 8)
	Primer 3R wt:	3'-Cttaatcttgatatagtagacctgggaaa-5'-CFET5 (SEQ ID NO: 9)
	Primer 3R mut:	3'-Attaatcttgatatagtagacctgggaaaag-5'-CFET6 (SEQ ID NO: 10)
25	Primer 4L:	3'-atagtagacctgggaaaagg-5' (SEQ ID NO: 11)
	Primer 4R wt:	3'-Tcgtgtgggacgtcttactcatacttgagt-5'-CFET9 (SEQ ID NO: 12)
30	Primer 4R mut:	3'-Gcgtgtgggacgtcttactcatacttgagtac-5'-CFET10 (SEQ ID NO: 13)

Table 3. The sequence of the two sets of synthetic templates (wt and mut)

5     Template A:

5'-gtaaaaatgactaattttttcttattccacag**T**gtatcggctagcctatc  
tcCggctaaatacactttgtgaacgccttctgtctgagcacccagaatta-3'  
(wild type) (SEQ ID NO: 14)

10    5'-gtaaaaatgactaattttttcttattccacag**A**gtatcggctagcctatc  
tc**T**ggctaaatacactttgtgaacgccttctgtctgagcacccagaatta-3'  
(mutated) (SEQ ID NO: 15)

Template B:

15    5'-tacactttgtgaacgccttctgtctgagcaccca**G**aattagaacatatca  
tctggaccctttttcc**A**gcacaccctgcagaatgagtatgaactcatgaga-3'  
(wild type) (SEQ ID NO: 16)

20    5'-tacactttgtgaacgccttctgtctgagcaccca**T**aattagaacatatca  
tctggaccctttttcc**C**gcacaccctgcagaatgagtatgaactcatgaga-3'  
(mutated) (SEQ ID NO: 17)

#### IV. CFET Tag Labeled Probes for Chromosome-wide Analysis

5 Probes can be generated using a random primed labeling method to incorporate CFET-dUTP into chromosome-specific DNA molecules or cosmids disposed along the length of a given chromosome. Metaphase spreads of fresh cells or deparaffinized material can be prepared by standard methodologies, and the tagged probes can be hybridized to the chromosomes. Bulky ET dyes consisting of two individual fluorescent molecules, as well as dyes with a long linker, have been attached to deoxynucleotides (dNTPs) and dideoxynucleotides (ddNTPs) which have been shown to be good substrates for DNA polymerase (Rosenblum et al. 1997, Zhu et al. 1994). Thus, the CFET-dUTP should be able to be incorporated into the growing strand by the polymerase reaction. In the actual random priming reaction, the ratio of regular deoxythymine triphosphate (dTTP) and CFET-dUTP can be adjusted, so that only a small portion of CFET-dUTP will be incorporated into the growing chain, just enough to be detected by the optical method.

25 Numerical and structural chromosome rearrangements are a major cause of human mortality and morbidity. Aneuploidy of whole chromosomes accounts for at least 50% of early embryonic lethality, and also leads to severe patterns of congenital malformation such as Down syndrome. Segmental aneuploidies due to deletions and duplications also lead to malformation

30

syndromes, as well as being associated with many types of cancer.

Traditional cytogenetic analysis is hampered by  
5 problems of resolution and interpretation inherent in  
standard banding analysis. In the last decade the use  
of fluorescent labeled DNA probes on chromosome  
preparations as well as on interphase nuclei has  
greatly improved the resolution and accuracy of  
10 cytogenetic diagnosis. Microdeletions and  
amplifications too small to be visible under the  
light microscope by banding can now be visualized  
using chromosome and region specific fluorescently  
labeled probes. Multiplexing this system is possible  
15 using combinations of probes labeled with different  
fluors. Sets of up to five differently labeled probes  
have been used for diagnostic purposes on interphase  
nuclei to determine aneuploidy in prenatal samples  
(Munne et al. 1998). M-FISH and Spectral Karyotyping  
20 use a combinatorial approach of five dyes to "paint"  
all 23 pairs of human chromosomes so they can be  
distinguished using computerized image software  
(Schrock et al. 1996, Speicher et al. 1996).  
However, these established techniques require careful  
25 mixing of dyes in controlled ratios. Quality control  
is often a problem, and the commercially available  
probes are very expensive.

CFET Tags are expected to have a substantial  
30 advantage over currently available dye sets. It  
should be possible to generate a larger number of  
CFET tag sets, reducing the need for a combinatorial  
approach. Quality control is also likely to be

easier, since each probe needs to be labeled with only one tag, and probe sets can be mixed in equal quantities to produce multicolor FISH reagents.

5 CFET Tags for example could be used both for the detection of aneuploidy in interphase nuclei, and for the detection of submicroscopic chromosomal deletions and amplifications. For aneuploidy detection, for example, a set of eight different CFET tag labeled  
10 probes can be prepared, each specific for one of the chromosomes most commonly involved in aneuploidy in either embryonic losses or birth defects (chromosomes 13, 15, 16, 18, 21, 22, X and Y).

15 A schematic of a procedure for comprehensive chromosome-wide analysis for gain or loss of genetic material is shown in Figure 10. In the example, eight probes each labeled with a CFET-dUTP that emits a unique fluorescence signature are hybridized along  
20 a chromosome in eight separate locations. The normal chromosome A will display eight unique fluorescence signatures of each probe in a defined order. A loss of fluorescence signature "2" in chromosome B will indicate the deletion of the complementary sequence  
25 of probe 2. Whereas, in chromosome C, the appearance of two signatures of "3" will indicate the expansion of the complementary sequences for probe 3.

30 Standard sets of cosmid and BisAcryloylCystamine (BAC) markers at 2-3 Mb intervals along the chromosomes are being developed in several laboratories, including a National Cancer Institute sponsored project, the Cancer Chromosome Aberration

Project (CCAP: webpage  
www.ncbi.nlm.nih.gov/ncicgap/). Sets of

differentially CFET-labeled ordered probes specific for particular chromosomal regions can be prepared. Using FISH, one can then determine the limits of suspected or known deletions.

#### V. Use of CFET Tags In Other Multi-Component Analyses

The CFET tags with unique fluorescence signatures which are disclosed in the present application will have utility in other applications involving multi component analysis in addition to those disclosed above. Additional applications include, but are not limited to, multiplex assays including binding assays and immuno assays, detection of microbial pathogens, monitoring multiple biomolecular reactions, screening of drugs or compounds, epitope mapping, allergy screening, and use with organic compounds and in material science. For example, multiple reactions or interactions can be measured simultaneously, where multiple CFET tags, each with a different fluorescence signature, are used to label the different reactants which could include, for example, antibodies, antigens, ligands, or substrates. Examples include antibody-antigen and receptor-ligand binding. In further examples, different reactants can be coupled to microspheres.

## VI. CFET Tags Used in Ligation Assay to Identify Multiple Single Nucleotide Polymorphisms.

As an example of application for biological assays, the CFET tags were applied to an oligonucleotide ligation assay (Landegren, 1988) coupled with solid phase purification to detect genetic mutations on exon 20 of the tumor suppressor retinoblastoma (RB1) gene. The schematic of the approach is shown in Fig. 11. Two 20 base-pair oligonucleotides, one labeled with a CFET tag at the 5' end and the other labeled with a biotin at the 3' end and a monophosphate (P) group at the 5' end, are hybridized to the target DNA template such that the 3' end of the CFET-labeled oligonucleotide is positioned next to the 5' end of the biotinylated oligonucleotide. Taq DNA ligase joins the two juxtaposed oligonucleotides in a head-to-tail fashion by forming a phosphodiester bond, provided that the nucleotides at the ligating junction of the two oligonucleotides are correctly base-paired with the template (Barany, 1991). Under the experimental conditions using Taq DNA ligase, no ligation reaction occurs when there is a mismatch between the 3' end of the CFET-labeled probe (nucleotides A and C, Fig. 11) and the SNP site (nucleotides T and G, Fig. 11) on the target template. After the ligation, the CFET-labeled ligation products (40 base-pair) are immobilized to streptavidin-coated magnetic beads while the other components are washed away. The ligation products are then cleaved from the magnetic beads by denaturing the biotin-streptavidin interaction with formamide and analyzed with a three-color fluorescence CAE

system. The CFET-labeled ligation products are unambiguously detected due to their distinct mobility and unique fluorescence signatures in the electropherogram, see Figure 12. In the case of heterozygotes at the SNP site, two CFET tags with different fluorescence signature and electrophoretic mobility are used to label the oligonucleotides corresponding to each allele. The unique fluorescence signatures in the electropherogram thus identify each of the corresponding SNPs. The solid phase procedure completely eliminates the unligated CFET-labeled oligonucleotide. Although the unligated 20 base-pair biotinylated oligonucleotides are also captured by the magnetic beads, they do not produce fluorescence signals due to the absence of CFET tags. The CFET tag library in this application detects multiple SNPs on the target DNA template simultaneously.

Exon 20 of the tumor suppressor RB1 gene (Schubert, 1994) was selected as a model system to test the utility of the CFET tags. Several SNPs within a region of 200 base pairs in the RB1 gene have been found, which are well suited for evaluating a genetic mutation analysis system. Six ligation reactions were carried out separately using six different CFET tags on synthetic templates mimicking exon 20 of the RB1 gene where multiple SNPs (six nucleotide variations) are located. After the ligation and solid phase purification, the ligation products were combined in a single tube and analyzed with a three-color CAE system, resulting in the simultaneous detection of six nucleotide variations by the unique fluorescence signatures of the CFET-labeled ligation products (see



Figure 12A). The unique fluorescence signatures were spatially resolved in the electropherogram as a result of the different mobility of the CFET-labeled ligation products. In this model experiment, both

5 CFET-1 (FAM) and CFET-6 (F-10-Cy5) detect homozygous SNPs (T/T). CFET-3 (F-9-T) and CFET-4 (F-13-T) clearly distinguish a mimic of RB1 gene mutation R661W (amino acid change from arginine to tryptophan due to mutation in codon 661) by detecting both the

10 wild type (C) and the mutation (T). CFET-7 (F-4-T-6-Cy5) and CFET-8 (F-7-T-7-Cy5) identify another mutation Q685P (amino acid change from glutamine to proline due to mutation in codon 685) with heterozygous genotype (A/C). To validate the CFET

15 technology further used three CFET-labeled oligonucleotide probes (CFET-1, 3 and 7) and their corresponding biotinylated oligonucleotides to identify three SNPs using a PCR product amplified from exon 20 of the RB1 gene from patient genomic

20 DNA. The ligation reactions were performed in a single tube and the reaction products were loaded onto a three-color CAE system. Three individual homozygous SNPs (T, C and A), that were verified by DNA sequencing, were unambiguously identified by the

25 three distinct fluorescence signatures from the CFET tags (figure 12B): T (FAM, CFET-1), C (F-9-T, CFET-3) and A (F-4-T-6-Cy5, CFET-7). Thus, the approach described here can detect both heterozygotes and homozygotes unambiguously because of the unique CFET

30 fluorescence signature and mobility in the electropherogram.

To increase the level of control available in isolation other isolation-permitting moieties besides biotin may be employed such as phenylboronic acid. Attachment of the moieties via cleavable linker molecules enhances this still further.

#### VII. CFET Tags Used in Single Base Primer Extension to Identify Multiple Single Nucleotide Polymorphisms.

Single base extension for each dye-labeled primer was done by mixing 0.5 to 1 pmol of the primers with 1 pmol of template, followed by adding 2  $\mu$ l of thermo sequenase 10X reaction buffer (260 mM Tris-HCl, 65 mM  $MgCl_2$ , pH 9.5, Amersham Pharmacia Biotech, Piscataway, NJ), 5  $\mu$ l of water, 1 pmol of biotinylated dideoxynucleoside triphosphates (Biotin-11-ddNTP, NEN, Boston, MA) and 1 unit of thermo sequenase in 20 mM Tris-HCl, pH 8.5, 50% glycerol, 0.1 mM ethylenediamine tetraacetic acid (EDTA), 0.5% Tween<sup>TM</sup>-20 (v/v), 0.5% Nonidet<sup>TM</sup> P-40 (v/v), 1mM dithiothreitol (DTT), 100 mM KCl and 0.053 unit/ $\mu$ l Thermoplasma acidophilum inorganic pyrophosphatase (Amersham Pharmacia Biotech). The reaction mixture was incubated at 54°C for 30 sec for single base extension.

Schematic representation of the multiplex SNPs detection using CFET tags and biotinylated dideoxynucleotides is shown in Figure 13. In this example, extension of the primers are initiated by ddCTP-Biotin (for primer 1) and ddGTP-Biotin (for primer 2) in the presence of DNA polymerase if there is a match between the 3' end of the primer and the

template (X and Y for primer 1; X' and Y' for primer 2). The extension products are isolated using streptavidin-coated magnetic beads. Upon denaturing, washing and releasing from the beads, the extension products are loaded onto an electrophoresis system and the resulting fluorescence signatures from the electropherogram identify each of the unique SNPs. Thus, the CFET-labeled oligonucleotides, DNA polymerase and biotinylated dideoxynucleotides form a high fidelity SNP detection system in which the base at the 3' end of the oligonucleotides dictates its extension by incorporating a specific biotinylated dideoxynucleotide. The CFET tags used were F, F-9-T and F-13-T. Their unique fluorescence signatures are shown in Figures 14 and 15

To increase the level of control over isolation, other isolation-permitting moieties such as phenylboronic acid, antigens or antibodies may be employed in place of the biotin. Attachment of the moieties via cleavable linker molecules enhances this still further.

#### VIII. High Throughput Analyses.

The throughput of the multiplex analyses offered by the use of the CFET tags can be increased by performing the analyses in the high throughput chamber illustrated in figure 16.

30

#### IX. In combination with non-FET tags.

To increase the number of different unique fluorescent signatures available in any set of tags

CFET tags can be used in combination with single chromophore/fluorophore tags and tags with multiple chromophores/fluorophores where no FET occurs. The number of possible different fluorescence signatures using such combinations is huge, and would greatly aid multiplex analyses. Such fluorophores could be quantum dots, luminescent molecules of fluorescent dyes. For example, each tag could be used to detect a different SNP using the exemplified assays.

### References

U.S. Patent No. 6,028,190 issued February 22, 2000,  
Mathies et al.

5

Barany, F. (1991) Genetic disease detection and DNA  
amplification using cloned thermostable ligase. *PNAS*.  
88:189-193.

10

Benson, S. C., Mathies, R. A. & Glazer, A. N. (1993).  
Heterodimeric DNA-binding dyes designed for energy  
transfer: stability and applications of the DNA  
complexes. *Nucleic Acids Res.* 21: 5720-5726.

15

Benson, S. C., Singh, P. & Glazer, A. N. (1993).  
Heterodimeric DNA-binding dyes designed for energy  
transfer: synthesis and spectroscopic properties.  
*Nucleic Acids Res.* 21: 5727-5735.

20

Chee, M., Yang, R., Hubbell, E., Berno, A., Huang, X.-  
C., Stern, D., Winkler, J., Lockhart, D. J., Morris,  
M. S., Fodor, S. P. (1996). Accessing genetic  
information with high-density DNA arrays. *Science*.  
274:610-614.

25

Chen, X. and Kwok, PY. (1997) Template-directed dye-  
terminator incorporation (TDI) assay: a homogeneous  
DNA diagnostic method based on fluorescence resonance  
energy transfer *Nucl. Acids. Res.* 25: 347-353.

30

Eggerding FA (1995) A one-step coupled amplification  
and oligonucleotide ligation procedure for multiplex  
genetic typing. *PCR Methods Appl.* 4: 337-345.

Fischer, S.G., Cayana, E., de Fatima Bonaldo, M., Bowcock, A.M., Deaven, L.L., Edelman, I.S., Gallardo, T., Kalachikov, S., Lawton, L., Longmire, J.L., Lovett, M., Osborne-Lawrence, S., Rothstein, R., Russo, J.J., Soares, M.B., Sunjevaric, I., Venkataraj, V.S., Warburton, D., Zhang, P. and Efstratiadis, A. (1996) A high-resolution annotated physical map of the human chromosome 13q12-13 region containing the breast cancer susceptibility locus BRCA2. *Proc. Natl. Acad. Sci. U.S.A.* 93: 690-694.

Förster, T. (1965) In: *Modern Quantum Chemistry, Istanbul Lectures, Part III*. Sinanoglu, O. (editor), Academic Press, New York, pp 93-137.

Glazer, A.N., Stryer, L. (1983) Fluorescent tandem phycobiliprotein conjugates. Emission wavelength shifting by energy transfer. *Biophys. J.* 43(3):383-386.

Hacia J.G., Edgemon K., Sun B., Stern D., Fodor S.A., Collins F.S. (1998). Two Color Hybridization Analysis Using High Density Oligonucleotide Arrays and Energy Transfer Dyes *Nucleic Acids Research* 15; 26: 3865-6

Ju, J., Glazer, A.N. & Mathies, R.A. (1996) Cassette labeling for facile construction of energy transfer fluorescent primers. *Nucleic Acids Res.* 24, 1144-1148.

- Ju J, Glazer AN and Mathies RA (1996) Energy transfer primers: A new fluorescence labeling paradigm for DNA sequencing and analysis. *Nature Medicine* 2: 246-249.
- 5 Ju J, Ruan C, Fuller CW, Glazer AN and Mathies RA (1995) Energy transfer fluorescent dye-labeled primers for DNA sequencing and analysis. *Proc. Natl. Acad. Sci. USA* 92: 4347-4351.
- 10 Ju J, Yan H, Zaro M, Doctolero M, Goralski T, Konrad K, Lachenmeier E and Cathcart R (1997) DNA sequencing with solid phase captureable terminators. *Microb. Comp. Genomics* 2: 223.
- 15 Kalachikov, S. et al. (1997) Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. *Genomics* 42(3): 369-377.
- 20 Landegren U, Kaiser R, Sanders J and Hood L (1988) A ligase-mediated gene detection technique. *Science* 241: 1077-1080.
- 25 Lee LG, Spurgeon SL, Heiner CR, Benson SC, Rosenblum BB, Menchen SM, Graham RJ, Constantinescu A, Upadhyia KG and Cassel JM (1997) New energy transfer dyes for DNA sequencing. *Nucleic Acids Res.* 25: 2816-2822.
- 30 Lohmann DR (1999) RB1 gene mutations in retinoblastoma. *Hum Mutat.* 14: 283-288
- Maxam AM and Gilbert W (1977) A new method for sequencing DNA. *Proc Natl. Acad. Sci. USA* 74: 560-564.

- Munne S, Magli C, Bahce M, Fung J, Legator M, Morrison L, Cohert J, Gianaroli. (1998) Preimplantation diagnosis of the aneuploidies most commonly found in spontaneous abortions and live births: XY, 13, 14, 15, 16, 18, 21, 22. *Prenat Diagn.* 18: 1459-66.
- Qu, X., Hauptschein, R.S., Rzhetsky, A., Scotto, L., Chien, M., Ye, X., Frigeri, F., Rao, P.H., Pasqualucci, L., Gamberi, B., Zhang, P., Chaganti, R.S.K., Dalla-Favera, R. and Russo, J.J. (1998) Analysis of a 69 kb contiguous genomic sequence at a putative tumor suppressor gene locus on human chromosome 6q27. *DNA Seq.* 9: 189-204.
- Rosenblum, B.B., Lee, L.G., Spurgeon, S.L., Khan, S.H., Menchen, S.M., Heiner, C.R., Chen, S.M. (1997). New dye-labeled terminators for improved DNA sequencing patterns. *Nucleic Acids Res* 25: 4500-4
- Rye, H. S., Drees, B. L., Nelson, H. C. M. & Glazer, A. N. (1993). Stable fluorescent dye-DNA complexes in high sensitivity detection of protein-DNA interactions. Application to heat shock transcription factor. *J. Biol. Chem.* 268: 25229-25238.
- Sambrook et al., "Molecular Cloning: A Laboratory Manual", Second Edition (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.



- Sanger F, Nickeln S and Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA* 74: 5463-5467.
- 5 Saxon E and Bertozzi CR (2000), Cell Surface Engineering by a Modified Staudinger Reaction. *Science*, 287: 2007-2010.
- 10 Schena, M., Shalon D., Davis, R. and Brown P.O. (1995) Quantitative monitoring of gene expression patterns with a cDNA microarray. *Science* 270:467-470.
- 15 Schrock E, du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith MA, Ning Y, Ledbetter DH, Bar-Am I, Soenksen D, Garini Yand Ried T (1996) Multicolor spectral karyotyping of human chromosomes. *Science* 273: 494-497.
- 20 Schubert EL, Hansen MF and Strong LC (1994). The retinoblastoma gene and its significance. *Ann Med.* 26: 177-184.
- 25 Smith, L. M., Sanders, J.Z., Kaiser, R. J., Hughes, P., Dodd, C., Connell, C. R., Heiner, C., Kent, S.B.H. and Hood, L. E. (1986). Fluorescence detection in automated DNA sequencing analysis. *Nature*. 321: 674-679.
- 30 Speicher MR, Ballard SG and Ward DC (1996) Karyotyping human chromosomes by combinatorial multi-fluor FISH. *Nature Genet.* 12: 368-375.

Stryer, L. (1978) Fluorescence energy transfer as a spectroscopic ruler. *Annu. Rev. Biochem.* **47**: 819-846.

5 Tabor, S. & Richardson, C. C. A single residue in DNA polymerases of the Escherichia coli DNA polymerase I family is critical for distinguishing between deoxy- and dideoxyribonucleotides. 1995. *Proc. Natl. Acad. Sci. U.S.A.* **92**: 6339-6343.

10 Uetz, et. al; and S. Fields (2000) A comprehensive analysis of protein-protein interactions in *Saccharomyces cerevisiae*. *Nature* **403** (Number 6770) 623 - 627.

15 Vogel. (1989) Textbook Of Practical Organic Chemistry, Fifth Edition, Addison Wesley Longman, Harlow, U.K.

20 Wu DY and Wallace RB (1989) The ligation amplification reaction (LAR): Amplification of specific DNA sequences using sequential rounds of template-dependent ligation. *Genomics* **4**: 560-569.

25 Xu, G-L. wt al. (1999) Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. *Nature* **402**: 187-191.

30 Zhu Z ; Chao J ; Yu H ; Waggoner AS (1994). Directly labeled DNA probes using fluorescent nucleotides with different length linkers. *Nucleic Acids Res*, **22**: 3418-22.

What is claimed is:

1. A composition of matter comprising multiple fluorophores, each of which is bound to a molecular scaffold at a separate predetermined position on the scaffold, such separate predetermined positions being selected so as to permit fluorescence energy transfer between one such fluorophore and another such fluorophore, wherein the one such fluorophore and the another such fluorophore are characterized by the maximum emission wavelength of one being greater than the minimum excitation wavelength of the other.
2. A composition of matter of claim 1 comprising two fluorophores, each of which is bound to a molecular scaffold, at a separate predetermined position on the scaffold, such separate positions being selected so as to permit fluorescence energy transfer between such fluorophores, and such fluorophores being characterized by the maximum emission wavelength of one of the fluorophores being greater than the minimum excitation wavelength of the other fluorophore.
3. A composition of matter of claim 1 comprising three fluorophores each of which is bound to a molecular scaffold at a separate predetermined position on the scaffold, such separate predetermined positions being selected so as to permit fluorescence energy transfer among such

fluorophores and such fluorophores being characterized by the maximum emission wavelength of one such fluorophore being greater than the minimum excitation wavelength of the second such fluorophore and the maximum emission wavelength of such second fluorophore being greater than the minimum excitation wavelength of the third such fluorophore.

- 10 4. The composition of matter of the claim 1, wherein each fluorophore is covalently bound to the molecular scaffold.
- 15 5. The composition of claim 1, wherein the efficiency of the fluorescence energy transfer is less than 20%.
- 20 6. The composition of claim 1, wherein the molecular scaffold is rigid.
7. The composition of claim 1, wherein the molecular scaffold is polymeric.
- 25 8. The composition of claim 9, wherein the molecular scaffold comprises a nucleic acid.
9. The composition of claim 9, wherein the molecular scaffold comprises a peptide.
- 30 10. The composition of claim 9, wherein the molecular

scaffold comprises a polyphosphate.

11. The composition of claim 1, wherein at least one fluorophore is a fluorescent dye.

5

12. The composition of claim 11, wherein the fluorescent dye is 6-carboxyfluorescein.

10

13. The composition of claim 11, wherein the fluorescent dye is N,N,N',N'-tetramethyl-6-carboxyrhodamine.

14. The composition of claim 11, wherein the fluorescent dye is cyanine-5 monofunctional dye.

15


15. The composition of claim 11, wherein at least one fluorophore is a luminescent molecule.

20

16. The composition of claim 11, wherein at least one fluorophore is a quantum dot.

17. A composition of matter having the structure:

25



wherein S represents a 1',2'-dideoxyribose  
phosphate moiety, m is an integer greater than 1  
and less than 100, each T represents a thymidine  
5 derivative, FAM represents 6-carboxyfluorescein  
derivative, TAM represents N,N,N',N'-tetramethyl-  
6-carboxyrhodamine derivative, each solid line  
represents a covalent bond, R represents either a  
hydroxy or phosphate terminus and Q represents  
10 either a hydroxy or phosphate terminus, with the  
proviso that R and Q are different.

18. The composition of claim 17, wherein m is 4.

15 19. The composition of claim 17, wherein m is 6.


20. The composition of claim 17, wherein m is 9.

21. The composition of claim 17, wherein m is 13.

20


22. A composition of matter having the structure:

25



wherein S represents a 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, T represents a thymidine derivative, FAM represents a 6-carboxyfluorescein derivative, Cy5 represents a cyanine-5 monofunctional dye derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q are different.

23. The composition of claim 22, wherein m is 4.
24. The composition of claim 22, wherein m is 5.
25. The composition of claim 22, wherein m is 7.
26. The composition of claim 22, wherein m is 10.
27. The composition of claim 22, wherein m is 13.
28. A composition of matter comprising the structure shown below:




5 wherein S represents a 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, n is an integer greater than 1 and less than 100, T represents a thymidine derivative, FAM represents a 6-carboxyfluorescein derivative, Cy5 represents a cyanine-5 monofunctional dye derivative, TAM represents a N,N,N',N'-tetramethyl-6-carboxyrhodamine  
10 derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q are different.

15

29. The composition of claim 28, wherein m is 3, and n is 7.
- 20 30. The composition of claim 28, wherein m is 4, and n is 6.
31. The composition of claim 28, wherein m is 5, and n is 5.
- 25 32. The composition of claim 28, wherein m is 6, and n is 6.
33. The composition of claim 28, wherein m is 7, and n is 7.



34. A composition of matter comprising the structure shown below:



10

15

20

wherein S represents a 1',2'-dideoxyribose phosphate moiety, m represents an integer greater than 1 and less than 100, T represents a thymidine derivative, and TAM represents a N,N,N',N'-tetramethyl-6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q are different.

35. The composition of claim 34, wherein m is 4.

25

36. A nucleic acid labeled with the composition of any of claims 1, 17, 22, 28 and 34.

37. The nucleic acid of claim 36, wherein the nucleic acid is DNA.

38. The nucleic acid of claim 36, wherein the nucleic acid is RNA.

5 39. The nucleic acid of claim 36, wherein the nucleic acid is DNA/RNA.

10 40. A method of determining whether a preselected nucleotide residue is present at a predetermined position within a nucleic acid comprising the steps of:

15 contacting the nucleic acid, under hybridizing and DNA ligation-permitting conditions, with (i) a DNA ligase, (ii) a first oligonucleotide having affixed thereto a composition of matter of claim 1 wherein the first oligonucleotide hybridizes with nucleotides immediately adjacent one side of the predetermined position and (iii) a second oligonucleotide which hybridizes with the nucleotides immediately adjacent the other side of the predetermined position, wherein the hydroxy-terminal residue of the oligonucleotide which hybridizes to the nucleotide located 3' of the predetermined position is a nucleotide which is complementary to the preselected nucleotide residue; and

20 25 30 (b) detecting the presence of a ligation product comprising both the first and the

second oligonucleotides, the presence of such a ligation product indicating the presence of the preselected nucleotide residue at the predetermined position.

5

41. A method of determining whether at various predetermined positions within a nucleic acid, a preselected nucleotide residue is present at such position, wherein the preselected nucleotide residue may vary at different predetermined positions which comprises determining whether each preselected nucleotide is present each predetermined position according to the method of claim 42.

15

42. The method of claim 41, wherein the presence of a plurality of given nucleotide residues is determined simultaneously.

20

43. The method of claim 40, wherein the DNA ligase is Taq DNA ligase.

25

44. The method of claim 40, wherein the second oligonucleotide has an isolation-permitting moiety affixed thereto, and wherein the method further comprises the steps of isolating the moiety-containing molecules resulting from step (a) and determining the presence therein of ligated first and second oligonucleotides.

30

45. The method of claim 40, wherein the composition of matter affixed to the first oligonucleotide has a predetermined emission spectrum, and wherein the observation of this emission spectrum is employed to determine the presence of ligated first and second oligonucleotides in step (b).

46. A method of determining whether a preselected nucleotide residue is present at a predetermined position within a nucleic acid comprising the steps of:

(a) contacting the nucleic acid, under hybridizing and DNA polymerization-permitting conditions, with (i) a DNA polymerase, (ii) an oligonucleotide (1) having affixed thereto a composition of matter of claim 1, and (2) having a hydroxyl 3' terminus thereof, wherein the oligonucleotide hybridizes with the 3' region of the nucleic acid molecule flanking the predetermined position, and (iii) a dideoxynucleotide labeled with an isolation-permitting moiety, wherein the labeled dideoxynucleotide is complementary to the given nucleotide residue,

with the proviso that upon hybridization of the oligonucleotide with the nucleic acid in the presence of DNA polymerase and the preselected nucleotide residue, the oligonucleotide and dideoxynucleotide are juxtaposed so as to permit their covalent

linkage by the DNA polymerase;

- (b) detecting the presence of a polymerization product comprising both the oligonucleotide and the dideoxynucleotide, the presence of such a polymerization product indicating the presence of the preselected nucleotide residue at the predetermined position.

47. A method of determining whether at various predetermined positions within a nucleic acid, a preselected nucleotide residue is present at such position, wherein the preselected nucleotide residue may vary at different predetermined positions which comprises determining whether each preselected nucleotide is present each predetermined position according to the method of claim 46.

48. The method of claim 46, wherein the DNA polymerase is thermo sequenase.

49. The method of claim 46, wherein the dideoxynucleotide is selected from the group consisting of dideoxyadenosine triphosphate, dideoxycytidine triphosphate, dideoxyguanosine triphosphate, dideoxythymidine triphosphate, and dideoxyuridine triphosphate.

50. The method of claim 46, wherein the composition of matter affixed to the oligonucleotide has a

predetermined emission spectrum, and wherein the observation of this emission spectrum is employed to determine the presence of polymerization product in step (b).

5

51. The method of claim 45 or 50, wherein observing the predetermined emission spectrum is performed using radiation having a wavelength of between 200 and 1000nm.

10

52. The method of claim 51, wherein the radiation has a wavelength of 488 nm.

15

53. The method of claim 45 or 50 wherein observing the predetermined emission spectrum is performed using radiation having a bandwidth of between 1 and 50nm.

20

54. The method of claim 53, wherein the radiation bandwidth is 1nm.

25

55. The method of claim 44 or 46, wherein the isolation-permitting moiety comprises biotin, streptavidin, phenylboronic acid, salicylhydroxamic acid, an antibody or an antigen.

56. The method of claim 55, wherein the isolation-permitting moiety is attached to the

oligonucleotide via a linker molecule.

57. The method of claim 46, wherein the isolation-permitting moiety is attached to the dideoxynucleotide via a linker molecule.

58. The method of claim 56 or 57, wherein the linker molecule is chemically cleavable.

59. The method of claim 56 or 57, wherein the linker molecule is photocleavable.

60. The method of claim 59, wherein the linker molecule has the structure:




Figure 1A






Figure 1B






Figure 2



(A)





Figure 3





Figure 4







Figure 6



\* This proline derivative can be prepared from acrylonitrile derivative and diethyl malonate according to the published literature Vogel's Textbook of Practical Organic Chemistry, 1989, Fifth Edn. p. 758 Longman




Figure 7






Figure 8








11/17


PCT/US01/28967

Figure 10

A: Normal Chromosome



B: Chromosome with marker 2 deleted (Deletion)



C: Chromosome with 2 copies of marker 3 (Expansion)




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15





Figure 16





## SEQUENCE LISTING

<110> Ju, Jingyue  
Russo, James J  
Tong, Anthony  
Li, Zengmin

<120> Combinatorial Fluorescence Energy Transfer Tags And  
Their Applications For Multiplex Biological Analyses

<130> 0575/62238A/JPW/ADM

<140>

<141>

<150> 09/658,077

<151> 2000-09-11

<160> 17

<170> PatentIn Ver. 2.1

<210> 1

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: scaffold

<400> 1

tttttttttt tttttttttt tttttc

26

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 2

ttaaaaagaa taagggtgtc

20

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 3

acatagccga tcggaatagag

20

<210> 4

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 4

tcatagccga tcggaatagag gc

22

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 5

acatagccga tcggaatagag

20

<210> 6

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 6

gccgatttat gtgaaacact tgcg

24

<210> 7

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 7

accgatttat gtgaaacact tgcgga

26

<210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 8

cggaagacag actcgtgggt

20

<210> 9

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 9

cttaatcttg tatagtagac ctgggaaa

28

<210> 10

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 10

attaatcttg tatagtagac ctgggaaaag

30

<210> 11

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 11

atagtagacc tgggaaaagg

20

<210> 12

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 12

tcgtgtggga cgtcttactc atacttgagt

30

<210> 13

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 13

gcgtgtggga cgtcttactc atacttgagt ac

32

<210> 14

<211> 100

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: template

<400> 14

gtaaaaatga ctaatttttc ttattccac agtgtatcgg ctagcctatc tccggctaaa 60  
tacactttgt gaacgccttc tgtctgagca cccagaatta 100

<210> 15

<211> 100

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: template

<400> 15

gtaaaaatga ctaatttttc ttattccac agagtatcgg ctacgcctatc tctggctaaa 60  
tacactttgt gaacgccttc tgtctgagca cccagaatta 100

<210> 16

<211> 100

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: template

<400> 16

tacactttgt gaacgccttc tgtctgagca cccagaatta gaacatatca tctggaccct 60  
tttccagcac accctgcaga atgagtatga actcatgaga 100

<210> 17

<211> 100

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: template

<400> 17

tacactttgt gaacgccttc tgtctgagca cccataatta gaacatatca tctggaccct 60  
tttccgcgac accctgcaga atgagtatga actcatgaga 100

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/US01/28967

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12Q 1/68; C07H 21/04

US CL : 435/6, 91.2; 536/23.1, 24.3

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 91.2; 536/23.1, 24.3

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
CAPLUS, MEDLINE, SCISEARCH, WEST, DERVENT

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4,824,775 A (DATTA GUPTA et al) 25 April 1989, see the entire document.	1-8, 11, 15 ----- 9-10, 12-14, 16
Y		
X	US 5,952,180 A (JU) 14 September 1999, see the entire document.	1-16
Y	US 5,945,283 A (KWOK et al) 31 August 1999, see the entire document.	1-16
X	US 5,804,386 A (JU) 08 September 1998, see the entire document.	1-16
X	US 5,654,419 A (MATHIES et al) 05 August 1997, see the entire document.	1-15 --- 16
Y		

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

06 JANUARY 2002

Date of mailing of the international search report

23 JAN 2002

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-9230

Authorized officer

PADMASREE PONNKLURI

Telephone No. (703) 305-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US01/28967

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,834,203 A (KATZIR et al) 10 November 1998, see the entire document	1-16

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US01/28967

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-16

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US01/28967

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-16, drawn to a composition of matter comprising multiple fluorophores.

Group II, claim(s) 17-21, drawn to a composition of matter having the structure (differs from the group I composition, by different groups (scaffold, thymidine group and also Q and R).

Group III, claim(s) 22-27, drawn to a composition of matter of the structure (differs from the group II structure).

Group IV, claim(s) 28-33, drawn to a composition of matter of the structure (differs from the groups II and III structure).

Group V, claim(s) 34-35, drawn to a composition of matter of the structure (differs from the groups II-IV structure).

Group VI, claim(s) 36-39, drawn to a nucleic acid labeled with the composition.

Group VII, claim(s) 40-45, 51-56, 58-60, drawn to a method of determining whether a preselected nucleotide residue is present at a predetermined position (differs by the use of ligase).

Group VIII, claim(s) 46-60, drawn to a method of determining whether a preselected nucleotide residue is present at a predetermined position (differs by the use of polymerase).

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. The species are as follows:

If group I is elected, applicants are requested to elect one single species of the following: a) molecular scaffold (nucleic acid, peptide, polyphosphate); b) fluorophore; and

if group VI is elected applicants are requested to elect a single label composition of claims 1, 17, 22, 28 or 34.

The inventions listed as Groups I-VIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical feature of group I is a composition with multiple fluorophores bound to a molecular scaffold, which is known in the art, see US Patent 5,834,203 (Katzir et al). The reference discloses the use of multiple fluorophores in labeling nucleic acid, thus the inventions in this application lack unity.

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: the special technical feature is fluorophore, which are known in the art; and the nucleic acid scaffold is known in the art (see US Patent 5,834,203).